Clinical Trials Logo

PET clinical trials

View clinical trials related to PET.

Filter by:
  • None
  • Page 1

NCT ID: NCT05636748 Recruiting - Stroke Clinical Trials

The Origin and Role of Thromboembolism in the Pathogenesis of Ischaemic Stroke

TORPIS
Start date: February 28, 2023
Phase:
Study type: Observational

Ischaemic stroke is usually due to occlusion of a cerebral artery by thrombus. However, it is often difficult to identify the source of thrombus, or to confirm thrombus as a cause of ischaemic stroke. Moreover, it is debated whether thrombosis plays any role in certain types of stroke such as lacunar stroke. In preliminary studies, the investigators have evaluated a novel clinical grade thrombus-specific radiotracer, 18F-GP1, which has a high specificity for the glycoprotein IIb/IIIa receptor on activated platelets. The investigations have demonstrated that 18F-GP1 is highly sensitive to in vivo thrombus formation and demonstrates avid binding to thrombus associated with myocardial infarction, pulmonary embolism and aortic bioprosthesis. This study will use this imaging approach to define the role and origin of thrombus in patients with ischaemic stroke, cryptogenic stroke and lacunar stroke.The investigators will also assess its added clinical value in assessing patients with ischaemic stroke.

NCT ID: NCT05394909 Active, not recruiting - Glucocorticoids Clinical Trials

Ultra-short Glucocorticosteroids and Tocilizumab Therapy in GCA Patients

TOPAZIO
Start date: February 7, 2020
Phase:
Study type: Observational

The objective of our study is to evaluate the functional and morphological imaging variations at 24 and 52 weeks compared to baseline during TCZ-treatment and 6 months after the suspension of TCZ. We will also evaluate the variations of aortic dilatation during the study period using the PET/CT in comparison with an hystorical cohort of patients with LVV treated with GCs only and longitudinally followed at our rheumatology division.

NCT ID: NCT03943966 Completed - Stroke Clinical Trials

In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer

iThrombus
Start date: November 11, 2019
Phase: N/A
Study type: Interventional

To date, the investigators have successfully employed a radiotracer (18F-sodium fluoride) as a marker of necrotic inflammation in human atherosclerosis. The investigators aim to further the mechanistic understanding of atherothrombosis by studying the activation of glycoprotein IIb/IIIa receptors in cardiovascular thrombus using the novel platelet radiotracer (18F-GP1). Binding of 18F-GP1 to activated platelets in venous and arterial thrombi has already been demonstrated in pre-clinical studies and a phase 1 trial in man. If successful, this study would define the role of the glycoprotein IIb/IIIa receptor within in vivo thrombosis across a range of cardiovascular diseases.

NCT ID: NCT03909828 Not yet recruiting - Parkinson Disease Clinical Trials

Precision Medical Diagnosis for Parkinson's Disease ─ The Quantitative Analysis System for PET/MRI Images in Patients

Start date: April 2019
Phase:
Study type: Observational

In nuclear medicine PET examinations, labeled radiopharmaceuticals are possible to enter the putamen and caudate nucleus regions of the striatum in the brain by intravenous injection. The severity of Parkinson's disease is assessed and diagnosed by quantitative analysis of the defect in the image of the radiopharmaceuticals. Clinical studies often use manual selection of regions of interest (ROIs) for quantitative analysis. However, this method causes human error and low reproducibility due to subjective factors, and also considerable time consuming. Therefore, in order to solve the above problems, this research project plans to build an automated quantitative analysis system for PET/MRI images. The quantitative analysis of the PET images is performed automatically by using the putamen and caudate ROI segmented by the MRI images. This automated quantitative analysis system is expected to improve the time-consuming, low reproducibility, and subjectivity problems of traditional manual ROI selection method, and provide a useful tool for the diagnosis of early PD. In the first year, this sub-project is expected to perform MRI T1 and 18F-FDOPA PET scanning of before and after acupuncture-treated PD patients provided by sub-project 3. In the second year, the correlation analysis will be made with the results of tremor test provided by sub-project 1 and that of the 99mTc-TRODAT SPECT image quantification provided by sub-project 4.

NCT ID: NCT00598286 Completed - Brain Imaging Clinical Trials

PET Imaging of Cannabinoid CB1 Receptors Using [18F]FMPEP-d2

Start date: January 2008
Phase: Phase 1
Study type: Interventional

The purpose of this protocol is to measure brain CB1 receptors in the hope to better understand how they work, so that one day we can understand how the CB1 receptors are involved in psychiatric, neurological, and behavioral disorders.